← Back

PharmaResources (Shanghai) Co. Ltd. A

PharmaResources (Shanghai) Co., Ltd., together with its subsidiaries, operates as a one-stop integrated service provider for new drug research, development, and commercial manufacturing to pharmaceutical and biotechnology companies in China and internationally. The company offers contract research organization (CRO), contract manufacturing organization (CMO), contract development and manufacturing organization (CDMO), and commercial manufacturing services for small molecule drugs. It is also involved in the research, development, and customized/commercial production of active pharmaceutical ingredients and key intermediates, including ticagrelor, oxiracetam, l-carnitine, velpatasvir, peramivir trihydrate, huperzine A, and vitamin K2, as well as design, screening, and optimization of hit compounds and lead compounds; conducting of structural improvements; and provision of preliminary safety screening to obtain candidate compounds with outstanding drug properties and intellectual property rights. In addition, the company provides medicinal chemistry, process research and development, pharmaceutical research, molecular building blocks, and pharmacokinetics services. Further, it engages in pharmaceutical technology research and development activities. PharmaResources (Shanghai) Co., Ltd. was founded in 2007 and is based in Shanghai, China.

Price · split & dividend adjusted
News & notes moving 301230.CS
Biotech & Genomic Medicine

Joinn Laboratories hits 3rd upper limit in 5 days as lab monkey prices double in a year

Shares of lab animal concept stocks remain active, with Joinn Laboratories hitting the daily upper limit today, marking its third upper limit in five trading days. The company expects attributable net profit for the first half of 2026 to be between 600 million and 900 million yuan, a year-on-year increase of 884.9% to 1,377.4%. The surge in performance is mainly due to rising market prices for lab monkeys combined with natural growth appreciation. According to data from the Chinese Government Procurement Network, the procurement unit price of cynomolgus monkeys rose from 92,000 yuan in May 2025 to 190,000 yuan in June 2026. A research report from Zheshang Securities points out that domestic annual demand for lab monkeys has exceeded 40,000, with a shortfall of nearly 10,000. It is estimated that the supply-demand gap will be at least 15,000 to 20,000 from 2026 to 2028, and monkey prices may remain elevated.
央广财经·42dRead more ▾